Silk Voice
Commercial- Indications
- Vocal fold augmentation
Company intelligence / Profile preview
Silk Biomaterials has developed a silk fibroin scaffold technology that leverages the biocompatibility and regenerative properties of natural silk. Their most advanced program targets peripheral nerve damage with a first-in-human clinical trial initiated around late 2019. Preclinical studies in vascular grafts and orthobiologics have shown promising results[5]. The company aims to provide alternatives to current synthetic or animal-derived implants by using tunable silk scaffolds that promote endogenous tissue regeneration without requiring cell seeding or chemical treatments[1][3][5].
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Silk Biomaterials.